Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.

Clin J Am Soc Nephrol · 2024 · PMC11108248 · PMID 38277468

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Discussion In the original SCORED analysis, the predefined kidney-specific composite end point was reduced by 29% with sotagliflozin compared with placebo, a difference that did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.